Filter
440
Text search:
booster
Featured
Recommendations
37
New Publications
90
Language
Document type
No document type
194
Guidelines
104
Studies & Reports
55
Fact sheets
26
Manuals
18
Strategic & Response Plan
18
Situation Updates
8
Training Material
7
Brochures
4
Resource Platforms
2
Infographics
2
Videos
2
Countries / Regions
India
27
Global
23
Congo, Democratic Republic of
11
South Africa
11
Brazil
8
Western and Central Europe
8
Africa
8
Philippines
7
Mozambique
7
Ukraine
7
Senegal
6
Germany
6
Tanzania
6
Argentina
6
Namibia
6
Zambia
5
Latin America and the Carribbean
5
Nigeria
4
Colombia
4
Lesotho
4
East and Southern Africa
4
Ghana
3
Uganda
3
Kenya
3
Rwanda
3
Myanmar / Burma
3
Liberia
2
Zimbabwe
2
Nepal
2
Indonesia
2
Benin
2
West and Central Africa
2
South–East Asia Region
2
Western Pacific Region
2
Venezuela
2
Eastern Europe
2
Burkina Faso
1
Sierra Leone
1
Ethiopia
1
Niger
1
Haiti
1
Bangladesh
1
Switzerland
1
Burundi
1
Ecuador
1
Botswana
1
Madagascar
1
Chile
1
Middle East and North Africa
1
Eastern Europe and Central Asia
1
Fiji
1
Russia
1
Moldova
1
France
1
United Kingdom
1
Authors & Publishers
Publication Years
Category
Countries
156
Clinical Guidelines
71
Women & Child Health
23
Public Health
19
Key Resources
11
Capacity Building
4
Pharmacy & Technologies
2
Toolboxes
COVID-19
88
HIV
27
TB
24
Mental Health
18
NTDs
17
Polio
13
Refugee
13
Malaria
13
Pharmacy
10
Conflict
9
Rapid Response
8
Caregiver
8
Ebola & Marburg
5
Natural Hazards
5
Planetary Health
5
AMR
4
NCDs
4
Global Health Education
3
Disability
2
Cholera
2
Health Financing Toolbox
2
Specific Hazards
1
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been
...
Comment The Lancet Volume 397, ISSUE 10269, P72-74, January 09, 2021
Published:December 08, 2020DOI:https://doi.org/10.1016/S0140-6736(20)32623-4
The updates are based on evidence emerging from the: Ongoing monitoring of the disease. Protection that the population already developed against COVID-19 through previous infection or vaccination. Epidemiological situation, availability of diagnostic tests and access to therapeutic options.
This document offers public health guidance for the prevention and control of COVID-19 in reception centres, and other temporary accommodation facilities, in the context of the mass influx of Ukrainian people into the European Union (EU), the European Economic Area (EEA) and the Republic of Moldova.
...
an approach to optimize the global impact of COVID-19 vaccines, based on public health goals, global and national equity, and vaccine access and coverage scenarios, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, latest update: 21 January 2022
Available in English, F
...
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th
...
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat
...
Accessed 7 July 2015
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Vaccines are a critical tool in the battl
...
The war in Ukraine will have direct and indirect health consequences on conflict affected people, including internally displaced people and refugees. Governments in countries receiving refugees are providing them with access to healthcare. This document aims to provide information to guide individua
...
Report of the WHO Technical Advisory Group | 12 August 2016 | Geneva, Switzerland
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
Afr J Tradit Complement Altern Med. (2016) 13(4):123-131
Out of 400 questionnaires distributed to the participants, 389 were returned with data acceptable for analysis. Ages of the participants ranged from 18 to 75 years (Mean=43 + 11.6). Out of the 272 (69.9%) participants who conceded that th ...
Out of 400 questionnaires distributed to the participants, 389 were returned with data acceptable for analysis. Ages of the participants ranged from 18 to 75 years (Mean=43 + 11.6). Out of the 272 (69.9%) participants who conceded that th ...
21 January 2022
The overall threat posed by Omicron largely depends on four key questions: (i) how transmissible the variant is; (ii) how well vaccines and prior infection protect against infection, transmission, clinical disease and death; (iii) how virulent the variant is compared to other varian
...
